These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [Is melanosis coli a harmless secondary finding?]. Balás M; Toóth E; Kovács A Orv Hetil; 1986 Mar; 127(9):501-4. PubMed ID: 3960530 [No Abstract] [Full Text] [Related]
12. Colitis with wall thickening and edematous changes during oral administration of the powdered form of Qing-dai in patients with ulcerative colitis: a report of two cases. Kondo S; Araki T; Okita Y; Yamamoto A; Hamada Y; Katsurahara M; Horiki N; Nakamura M; Shimoyama T; Yamamoto T; Takei Y; Kusunoki M Clin J Gastroenterol; 2018 Aug; 11(4):268-272. PubMed ID: 29549501 [TBL] [Abstract][Full Text] [Related]
13. [The endoscopic and clinical features of Indigo Naturalis-associated ischemic lesions of colonic mucosa]. Suo BJ; Zhou LY; Ding SG; Lü YM; Gu F; Lin SR; Zheng YA Zhonghua Nei Ke Za Zhi; 2011 Aug; 50(8):646-9. PubMed ID: 22093554 [TBL] [Abstract][Full Text] [Related]
14. PillCam COLON 2 in Crohn's disease: A new concept of pan-enteric mucosal healing assessment. Boal Carvalho P; Rosa B; Dias de Castro F; Moreira MJ; Cotter J World J Gastroenterol; 2015 Jun; 21(23):7233-41. PubMed ID: 26109810 [TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis: A Single-Center Open-Label Prospective Study. Sugimoto S; Naganuma M; Kiyohara H; Arai M; Ono K; Mori K; Saigusa K; Nanki K; Takeshita K; Takeshita T; Mutaguchi M; Mizuno S; Bessho R; Nakazato Y; Hisamatsu T; Inoue N; Ogata H; Iwao Y; Kanai T Digestion; 2016; 93(3):193-201. PubMed ID: 26959688 [TBL] [Abstract][Full Text] [Related]
16. Role of colonoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis. Kirsch R; Pentecost M; Hall Pde M; Epstein DP; Watermeyer G; Friederich PW J Clin Pathol; 2006 Aug; 59(8):840-4. PubMed ID: 16873564 [TBL] [Abstract][Full Text] [Related]
17. Increase in permeability and phospholipase A2 activity of colonic mucosa in Crohn's colitis. Olaison G; Leandersson P; Sjödahl R; Tagesson C Digestion; 1989; 43(4):228-33. PubMed ID: 2612746 [TBL] [Abstract][Full Text] [Related]
18. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease. Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260 [TBL] [Abstract][Full Text] [Related]
19. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626 [TBL] [Abstract][Full Text] [Related]
20. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease. Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]